Compositions comprising siraitia grosvenori extracts and methods for the treatment of infection

a technology of siraitia grosvenori and extract, which is applied in the direction of biocide, plant growth regulator, plant ingredients, etc., can solve the problems of cirrhosis of the liver, hepatocellular carcinoma, decompensated liver disease and/or hepatocellular carcinoma

Inactive Publication Date: 2010-10-28
CASCADE ESTATES
View PDF6 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chronic hepatitis C virus is an insidious and slow-progressing disease having a significant negative impact on the quality of life.
It can eventually result in cirrhosis of the liver, decompensated liver disease and / or hepatocellular carcinoma.
Alpha interferon mono-therapy is commonly used to treat infection with chronic hepatitis C. However, this treatment is not always effective and sometimes results in intolerable side effects depending on the dosage and the duration of therapy.
However, this mono-therapy treatment has been found to be relatively ineffective and, furthermore, presents its own undesirable side effects.
However, the combined use of alpha interferon and Ribavirin does not eradicate HCV-RNA in a long-term, effective manner.
This causes the infected cells to function improperly and die prematurely, thus weakening the immune system.
HIV infection results in disturbances of the entire immune defense mechanism.
This HIV-induced T4 reduction results in the development of frequent and eventually fatal opportunistic infections caused by pathogenic organisms such as viruses, bacteria, protozoa or fungi.
However, their side effects are often so severe that treatment must be halted allowing HIV resistant strains to quickly develop.
These drugs ultimately slow down the replication of viral DNA.
However, they do not rid the body of the virus but merely act to slow down and reduce the severity of the development of the infection.
Many of the anti-viral therapies which are currently available are directed towards targeting viral components and are therefore prone to compensatory viral evasion mechanisms.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising siraitia grosvenori extracts and methods for the treatment of infection
  • Compositions comprising siraitia grosvenori extracts and methods for the treatment of infection
  • Compositions comprising siraitia grosvenori extracts and methods for the treatment of infection

Examples

Experimental program
Comparison scheme
Effect test

example 1

Anti-Viral Activity of Luo Han Guo Extract Against Bovine Viral Diarrhoea Virus

Materials and Methods

[0162]An extract of Luo Han Guo was obtained using the process described in U.S. Pat. No. 5,411,755 and tested for antiviral activity against Bovine Viral Diarrhoea Virus (BVDV), strain NADL. BVDV is a flavivirus in the same family as the human hepatitis C virus. Hepatitis C cannot be grown in tissue culture so BVDV is used as a model virus due to the structural similarities between these two viruses.

[0163]The Luo Han Guo extract can be stored at room temperature and is water soluble. The Luo Han Guo extract was tested independently at a wide range of concentrations. The extract was tested in two assays, one at 100, 50, 25, 12.5 and 6.25 μg / mL and the other at 3600, 1200, 400, 133.3 and 44.4 μg / mL.

[0164]Bos taurus (BT) turbinate cells were used as host cells for the virus. After the cells were plated and allowed to grow overnight, The extract was added and then the virus was inoculate...

example 2

Anti-Viral Activity of the Triterpene Glycoside Mogroside V Against HIV-1

Materials and Methods

[0172]Mogroside V was tested for efficacy against HIV-1 strain 111B using H9 cells as the viral host.

[0173]Mogroside V can be stored at room temperature in powder form and is water-soluble. Aqueous stock solution was stored at 4° C. Final reagent dilutions were made in growth media from the aqueous stock solution. Five dilutions of Mogroside V were used: 100, 36, 12, 6 and 2 μg / mL.

[0174]H9 cells were used as host cells for the virus. H9 is a human T cell clone selected for high yield permissive growth of HIV-1, cloned from Hut 78, a human T cell lymphoma cell line with an inducer / helper phenotype derived from the peripheral blood of a patient with Sezary Syndrome.

[0175]The virus used was HIV-1, Strain IIIB, Catalog No 10-124-000, Lot No. 6M0008-DP. HIV-1 IIIB infects H9 cells but does not consistently cause cytopathic effect (CPE) and therefore viral growth is measured by HIV-1 p24 antigen ...

example 3

Anti-Viral Activity of Luo Han Guo Extract Against Bovine Viral Diarrhoea Virus (BVDV) when Combined with Fluvastatin

Materials and Methods

[0189]Materials and methods were similar to those outlined in Example 1.

[0190]Fluvastatin must be stored between 0° and 5° C. and is water soluble. The extract and fluvastatin were tested in combination with two concentrations of the extract, an effective dose (100 ng / mL) and a dose below its effective range for BVDV (6 μg / mL), and five doses of fluvastatin in its effective range (0.313, 0.625, 1.25, 2.5, and 5.0 μg / mL).

Results

[0191]Table 4 shows the percent of negative control and inhibition index for the various concentrations of the extract and fluvastatin. Fluvastatin was shown to extend the lower range of the effectiveness of the extract. In particular, with 6 μg / mL of extract, the inhibition index for 5 and 0.3125 μg / mL fluvastatin was much improved over fluvastatin alone (FIG. 3) or extract alone (FIG. 1).

TABLE 4Percent of negative control ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

A method for the treatment and / or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one thterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one thterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.

Description

FIELD OF THE INVENTION[0001]The present invention relates to methods for the prophylaxis and / or treatment of viral infections, such as hepatitis C and HIV. The invention further relates to compositions for use in the treatment and / or prophylaxis of viral infections.BACKGROUND TO THE INVENTION[0002]Luo Han Guo (also known as Luo Han Kuo) is a fruit of the Siraitia grosvenori Swingle (formerly Momoridca grosvenori Swingle) belonging to the Cucurbitaceae species. These fruits are cultivated in parts of China and extract of the Luo Han Guo plant is currently manufactured and marketed as a natural low-calorie sweetener, for example, PURELO™. U.S. Pat. No. 5,411,755 describes a process for preparing a sweet juice from Luo Han Guo fruit. The sweetness of the extract from Luo Han Guo is due to the presence of highly stable triterpene glycosides, known as mogrosides, which are about 250 to 300 times sweeter than sucrose. These compounds possess a triterpene backbone with two to six glucose u...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K36/42A61K31/704A61P31/12A61P31/16A61P31/14A61P31/18A61P31/20A61P1/16A61P11/00
CPCA61K36/42A61K31/405A61K31/704A61P1/16A61P11/00A61P31/12A61P31/14A61P31/16A61P31/18A61P31/20A61P35/00Y02A50/30A61K45/06
Inventor PRENDERGAST, PATRICK T.
Owner CASCADE ESTATES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap